Figure 8.
Schematic representation of metformin/AMPK/ER signalling pathway and its potential crosstalk with bromocriptine/D2R pathway in prolactinoma treatment. Red arrow/line refers to regulatory relationship proposed in this study. Dashed line with question mark refers to potential AMPK‐independent pathway for BC/D2R to regulate ER expression